Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085183" target="_blank" >RIV/00216224:14110/15:00085183 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/15:10315984 RIV/65269705:_____/15:00063644 RIV/00843989:_____/15:E0105143 RIV/00064203:_____/15:10315984
Result on the web
<a href="http://dx.doi.org/10.1097/MBC.0000000000000298" target="_blank" >http://dx.doi.org/10.1097/MBC.0000000000000298</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/MBC.0000000000000298" target="_blank" >10.1097/MBC.0000000000000298</a>
Alternative languages
Result language
angličtina
Original language name
Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003
Original language description
Our objective was to assess the incidence of inhibitors development in Czech Republic since the introduction of recombinant factor VIII (rFVIII) and to look for the factors potentially influencing this parameter. It is to be expected that inhibitors riskmay be increased after the introduction of recombinant products. Data of Czech National Haemophilia Programme registry entered from 2003 till 2013 were analysed. Both annual and absolute incidences of newly developed inhibitors in previously untreated patients (PUPs) were calculated. Bleeding and treatment data were also extracted, and association to the treatment regimen and development of inhibitors were analysed. Within the given period, we commenced 45 PUPs with haemophilia A on rFVIII and treatedthem for 137 treatment-years. Twenty-two of the PUPs had severe haemophilia A, being treated for 88 treatment-years. Treatment strategy for them was prophylaxis. Other PUPs were treated on demand.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/EE2.4.12.0048" target="_blank" >EE2.4.12.0048: Hemophilia centres</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Coagulation and Fibrinolysis
ISSN
0957-5235
e-ISSN
—
Volume of the periodical
26
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
673-678
UT code for WoS article
000364400500013
EID of the result in the Scopus database
—